Tego Science acquires 95.77% of P&P Pharm
테고사이언스
191420
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=634
Risk-adjusted indicator based on 634 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Acquisition Amount: 3,735,000,000 KRW
- • Equity Ratio: 7.42% of Tego Science's equity
- • Acquired Stake: 95.77% of P&P Pharm
- • P&P Pharm 2025 Revenue: 4,954M KRW
- • P&P Pharm 2025 Net Income: 250M KRW
AI Analysis Summary
Tego Science, Inc. decided to acquire 49,800 shares of P&P Pharm for 3,735,000,000 KRW, representing 7.42% of Tego Science's equity. This acquisition will give Tego Science a 95.77% controlling stake in P&P Pharm, a pharmaceutical wholesaler. The acquisition aims to strengthen sales capabilities and expand business areas. P&P Pharm reported 2025 revenue of 4,954M KRW and net income of 250M KRW. The acquisition is expected to be completed by May 29, 2026, and is a strategic move for business expansion.
How This Event Is Evaluated
M&A / Merger Evaluation
M&A events are evaluated by assessing deal size relative to company scale, strategic rationale, financing structure, and integration risk.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Deal size relative to market value
- Strategic fit and synergy potential
- Financing structure (cash, stock, debt)
- Regulatory and integration risk
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.